EANS-Adhoc: Intercell AG / Intercell AG announces Q3 2011 results and provides an update on ongoing operations

--------------------------------------------------------------------------------
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
distribution. The issuer is solely responsible for the content of this
announcement.
--------------------------------------------------------------------------------

9-month report

08.11.2011

» IXIARO®/JESPECT® net product sales of EUR 15.5m in the first nine
months of 2011 - an increase of 65% compared to 2010

» Re-structuring measures successfully implemented - operating loss
for the first nine months of 2011 reduced by 63% compared to 2010

» Development programs progressing according to plan

» Significant progress in net loss-reduction (minus 72% in Q3) and
cash conservation (EUR 68.8m liquid funds at quarter-end)

Vienna (Austria), November 8, 2011 - Today, Intercell AG (VSE: ICLL)
announced its financial results for the third quarter of 2011 and
provided an update on its operations.

Financial results

» Year-on-year revenue growth of 22.7% for the first nine months
driven by strong IXIARO®/JESPECT® sales revenues.

» Net loss of EUR 7.8m in Q3 2011 and EUR 20.6m for the first 9
months of 2011.

» Cash position of EUR 68.8m at quarter-end.

» Unchanged net loss expectation of EUR 30-40m for full year 2011.

Key Financial Figures

TEUR 3 months ended 9 months ended Year ended
September 30 September 30 Dec 31,
2011 2010 2011 2010 2010

Revenues 7,527 6,704 25,904 21,118 34,215

Net profit/loss (7,754) (27,844) (20,620) (50,892) (255,182)

Net operating
cash flow (3,035) (22,724) (31,940) (49,218) (65,120)

Cash and marketable
securities,
end of period 68,791 107,141 68,791 107,141 86,182

IXIARO®/JESPECT®

The IXIARO®/JESPECT® sales revenues exceeded EUR 15m in the first nine months
2011 and showed a year-on-year revenue growth of 65% compared to the prior year.
Hence, the product sales development is progressing towards the company´s
expectations for a full year-on-year growth of 60-70% compared to 2010.

In September Intercell and its partner, Biological E. Ltd., announced
the successful completion of a pediatric pivotal Phase II/III study
for its vaccine to protect children from Japanese Encephalitis (JE).
Analysis of the pivotal Phase III safety and immunogenicity data
showed positive results, and the study met its primary endpoint.

The pediatric development program for IXIARO®/JESPECT® label
extension for children is progressing.

As an important step to fully license its Quality Control Operations
at the Vienna site, Intercell successfully passed a pre-approval
inspection by the U.S. Food and Drug Administration (FDA).

Re-structuring measures successfully implemented

The commercial operations at Intercell´s U.S. site in Gaithersburg
(MD) have been consolidated. The patch R&D activities have been
successfully transferred to Vienna. The transfer of facility leases
and sale of residual equipment is underway.

Update on development programs - good progress

Pseudomonas aeruginosa infections - In September Intercell received
positive scientific advice from the European Medicines Agency (EMA)
for an investigational Pseudomonas vaccine Phase II/III study.
Intercell is preparing for the pivotal clinical efficacy trial of the
Pseudomonas aeruginosa vaccine candidate in ventilated ICU (Intensive
Care Unit) patients.

Clostridium difficile vaccine candidate - Intercell received positive
first data from a Phase I clinical trial with the Company's vaccine
candidate, IC84, to prevent disease caused by the bacterium
Clostridium difficile (C. difficile). Data showed good safety and
immunogenicity of the vaccine candidate and indicates functionality
of the induced antibodies.

Pandemic Influenza Vaccine Enhancement Patch (VEP): The enrollment
for the confirmatory Phase I trial is nearing completion, and a first
safety analysis has been completed.

Hepatitis C: Romark is still awaiting regulatory clearance for study
initiation of a combination Phase II trial which is expected to start
in H2 2011. In the absence of receipt of regulatory clearance in the
near future, the trial will not proceed as expected.

The full report can be downloaded at http://www.intercell.com/main/fo
rinvestors/downloads/quarterly-reports/

Further inquiry note:
Intercell AG
Nina Waibel
Corporate Communications
Tel. +43 1 20620-1222
communications@intercell.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: Intercell AG
Campus Vienna Biocenter 3
A-1030 Wien
phone: +43 1 20620-0
FAX: +43 1 20620-800
mail: investors@intercell.com
WWW: www.intercell.com
sector: Biotechnology
ISIN: AT0000612601
indexes: ATX Prime
stockmarkets: official market: Wien
language: English